{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-26-000087","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2026-06-18T17:17:22+00:00","discovered_at":"2026-06-18T17:19:00.521851+00:00","generated_at":"2026-06-18T17:19:06.597017+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pfizer reaffirms FY2026 guidance after CFO transition; revenue $59.5-$62.5B, adj. EPS $2.80-$3.00","bullets":["Reaffirms FY2026 revenue guidance of $59.5-$62.5 billion.","Reaffirms FY2026 adjusted diluted EPS guidance of $2.80-$3.00.","Reaffirmation follows CFO transition announcement on June 18, 2026.","Guidance originally introduced Dec 16, 2025 and reaffirmed on Q1 2026 earnings call May 5, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-26-000087","json":"https://secwatch.observer/filing/0000078003-26-000087.json","markdown":"https://secwatch.observer/filing/0000078003-26-000087.md","text":"https://secwatch.observer/filing/0000078003-26-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000087/0000078003-26-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000087/pfe-20260618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T17:19:06.597017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}